Hong Kong gives conditional nod to Gilead COVID-19 drug Remdesivir


adds background

HONG KONG, July 17 (Reuters) - Gilead Sciences GIL.O medicine Remdesivir has received a conditional green light to be used to curb the coronavirus pandemic, Hong Kong officials said on Friday.

The Hong Kong unit of the California-based drugmaker has to continue to submit additional data on the safety, effectiveness and quality of Veklury, the active ingredient of which is Remdesivir, the Drug Office of Department of Health said on its website.

Remdesivir, which helped shorten hospital recovery times in a U.S. clinical trial, has been added to several countries' lists of treatments against the disease that has killed more than half a million people globally.

Hong Kong, home to more than 7 million people, has reported a total of 1,714 coronavirus cases and 11 deaths since late January.

(Reporting by Twinnie Siu Hong Kong, Roxanne Liu in Beijing; Editing by Catherine Evans and David Goodman)

((; (8610)6627-1277; Reuters Messaging:

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.